Taiwan To Kick Off Public/Private Biotech Funding Venture
This article was originally published in PharmAsia News
Taiwan plans to create a public-private biotechnology venture capital firm in an effort to build the industry as one of six the government has emphasized. The bioventure would receive 40 percent of its funds from the government, the rest to come from the private sector. The nation's Executive Yuan Council is earmarking up to $296 million in seed money for the first phase of the initiative. The five other industries, including pharmaceutical and healthcare industries, are to receive their own joint venture funding programs in the future. (Click here for more - a subscription may be required
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.